SEC	Form 4
-----	--------

 \Box

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to						
Section 16. Form 4 or Form 5						
obligations may continue. See						
Instruction 1(b).						

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Murphy Nicole						2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]								5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Owner Officer (give title Other (spe				vner	
(Last) 225 BIN	(F NEY STRI	,	(Middle))ate of /31/2(st Tran	nsaction (Month/Day/Year)					A below)	m Op	below)		
(Street) CAMBR	IDGE M	[A	02142		4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Lin	e) X Form	al or Joint/Group Filing (Check Applicable form filed by One Reporting Person form filed by More than One Reporting				
(City)	(S	tate)	(Zip)		Ru	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a c satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instru								contract, instruction or written plan that is intended to					
		Tab	le I - No	on-Deriv	ative	Sec	uritie	es Ac	quired	, Dis	sposed (of, or Be	neficia	lly Owne	d				
1. Title of Security (Instr. 3) Date (Month/Day					r) Exe	A. Deemed Execution Date, f any Month/Day/Year)		Transaction Disposed Code (Instr.		ies Acquired (A) or Of (D) (Instr. 3, 4 and		5) 5. Amount of Securities Beneficially Owned Followin Reported		Forn (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)	Price	Transac	Transaction(s) (Instr. 3 and 4)			(1150. 4)	
Common Stock 03/			03/31/	2023	2023		М		239			5,818	5,818.2903 ⁽¹⁾		D				
Common Stock 03/31/			2023						116	16 D \$2		3 5,702.2903			D				
		т	able II								osed of converti			y Owned					
1. Title of Derivative Security (Instr. 3) 2. 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date (Month/Day/Year) 1. Title of Derivative Security 2. 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date (Month/Day/Year)				ned on Date,	4. Transactic Code (Ins 8)		5. Number ion of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e S Ily I	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Unit	\$0	03/31/2023			М			239	(2)		04/01/2024	Common Stock	239	\$0	240		D		

Explanation of Responses:

1. Includes 91.6992 shares acquired under the Biogen Inc. employee stock purchase plan.

2. This award was granted to the reporting person on April 1, 2021. The remaining portion of the award vests in equal installments on each of the second and third anniversary of the grant date.

/s/ Wendell Taylor, attorney in

fact for Nicole Murphy

** Signature of Reporting Person Date

04/04/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.